Drug Trial Radar · NCT02542696
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Nov 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
496
Actual
Start
Aug 31, 2015
Primary completion
Nov 8, 2022
Study completion Nov 8, 2022
Sponsor
- Lead sponsor
- Sumitomo Pharma America, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 7, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
Conditions
- Parkinson Disease
Interventions
APL-130277Drug
Used to treat up to 5 "OFF" episodes per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of Safety and Tolerability Data Collected, Based on Number of Participants With Adverse Events in the LTS PhaseTime frame: up to approximately 3 years
Locations
70 sites in 8 countries. Site status is shown where the registry gives one.
University of Alabama Birmingham
Birmingham, Alabama
Muhammed Ali Parkinson and Movement Disorder Center/Barrow Neurological Institute
Phoenix, Arizona
Movement Disorders Center of Arizona
Scottsdale, Arizona
Clinical Trials, Inc.
Little Rock, Arkansas
The Parkinson's and Movement Disorder Institute
Fountain Valley, California
UC Irvine Health Gottschalk Medical Plaza
Irvine, California
Keck Medical Center at USC
Los Angeles, California
University of Colorado School of Medicine
Aurora, Colorado
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Parkinsons Disease and Movement Disorders Center
Boca Raton, Florida
University of Miami, Miller School of Medicine
Miami, Florida
Parkinson's Disease Treatment Center of Southwest Florida
Port Charlotte, Florida
Suncoast Neuroscience Associates Inc.
St. Petersburg, Florida
USF Parkinson's Disease and Movement Disorder Center
Tampa, Florida
Emory University Department of Neurology
Atlanta, Georgia
GRU Movement Disorders
Augusta, Georgia
Northwestern University
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
NorthShore Neurological Institute B043D
Glenview, Illinois
Central DuPage Hospital - Neurodegenerative Clinic - Movement Disorders Center
Winfield, Illinois
University of Iowa Dept. of Neurology
Iowa City, Iowa
Kansas University Medical Center-Department of Neurology
Kansas City, Kansas
University of Kentucky
Lexington, Kentucky
University of Maryland
Baltimore, Maryland
Johns Hopkins University
Baltimore, Maryland
Michigan State University - Dept. of Neurology
East Lansing, Michigan
QUEST Research Institute
Farmington Hills, Michigan
Henry Ford Hospital
West Bloomfield, Michigan
Park Nicolet Institute - Stuthers Parkinson's Center
Golden Valley, Minnesota
SUNY Downstate Medical Center, Department of Neurology
Brooklyn, New York
Bendheim Parkinson's and Movement Disorder Center (Mount Sinai Medical Center)
New York, New York
Columbia University Medical Center - Neurological Institute, Movement Disorders
New York, New York
Duke University - Movement Disorders Clinic
Durham, North Carolina
Raleigh Neurology Associates, P.A.
Raleigh, North Carolina
Wake Forest Baptist Health
Winston-Salem, North Carolina
University of Cincinnati
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
The Ohio State University Wexner Medical Center
Columbus, Ohio
UT Gardner-McMaster Parkinson's Center
Toledo, Ohio
The Movement Disorder Clinic of Oklahoma
Tulsa, Oklahoma
Showing 40 of 70 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.